Discover trends, market shifts, and competitive outlooks for the unresectable hepatocellular carcinoma industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Key Projections for the CAGR of the Unresectable Hepatocellular Carcinoma Market Size From 2025 to 2034?
In recent times, there has been a slight increase in the market size for unresectable hepatocellular carcinoma. The market, currently valued at $1.98 billion in 2024, is projected to expand to $2.01 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of 1.9%. This growth pattern in the historic period is attributable to a variety of factors such as advancements in chemotherapy, results of clinical trials, constraints in liver transplantation, a rise in cancer incidences, and increased accessibility to treatment options.
Expectations are high for the unresectable hepatocellular carcinoma market size, with strong expansion forecasted in the upcoming years. The prediction suggests a surge to $2.95 billion by 2029, with a compound annual growth rate (CAGR) of 10.0%. The imminent growth during the forecast period can be ascribed to changes in healthcare policies, strategies for patient stratification, the application of real-world evidence, heightened patient advocacy and awareness, along with economic factors and dynamics. The period is set to witness key trends including precision medicine and biomarkers, integration of real-world evidence and data, multidisciplinary approaches, worldwide clinical trials and partnerships, alongside a stronger focus on patient-centric care.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Unresectable Hepatocellular Carcinoma Market?
The surge in liver cancer rates is fueling the growth of the market for unresectable hepatocellular carcinoma. The term “liver cancer” refers to the transformation of healthy, functional liver cells into cancerous cells that multiply without restraint. Transplantation and radiofrequency ablation are typically used to treat unresectable hepatocellular carcinoma. As an example, the Journal of Hepatology, a peer-reviewed scientific journal from Switzerland, reported in October 2022 that 830,200 people worldwide succumbed to liver cancer by 2020. It is projected that between 2020 and 2040, there will be approximately 1.4 million new diagnoses of liver cancer, representing a 55.0% annual increase. In another report by the American Cancer Society, a US-based non-profit organization, it was estimated in January 2024 that 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer would be diagnosed in the US in 2024. This includes 28,000 men and 13,630 women, with a prediction of 29,840 deaths (19,120 men and 10,720 women). These growing incidences of liver cancer are behind the expanding unresectable hepatocellular carcinoma market.
Which Key Market Segments Comprise the Unresectable Hepatocellular Carcinoma Market and Drive Its Revenue Growth?
The unresectable hepatocellular carcinoma market covered in this report is segmented –
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer, Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma, Focal Nodular Hyperplasia, Hemangiomas
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12079&type=smp
Which Areas Are Leading Regions in the Unresectable Hepatocellular Carcinoma Market Expansion Across the Globe?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theUnresectable Hepatocellular Carcinoma Market Direction?
The introduction of innovative products is emerging as a significant trend in the unresectable hepatocellular carcinoma market. Leading companies in this market are introducing progressive products to maintain their market standing. A clear example of this was seen in October 2022, when AstraZeneca, a globally recognized pharmaceutical and biotech firm from the UK, unveiled its FDA-endorsed Imjudo (tremelimumab) in conjunction with Imfinzi, specifically for US-based patients suffering from inoperable liver cancer. This novel treatment approach, dubbed the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), comprises of a singular dose of the anti-CTLA-4 antibody Imjudo 300mg, and the anti-PD-L1 antibody Imfinzi 1500 mg, administered every four weeks. It was observed that patients undergoing this combined treatment of Imjudo and Imfinzi experienced a reduction of 22% in mortality rates compared to those undergoing sorafenib treatment.
View the full report here:
How Is the Unresectable Hepatocellular Carcinoma Market Conceptually Defined?
Unresectable hepatocellular carcinoma refers to an aggressive tumor that typically develops alongside cirrhosis and chronic liver disease. The treatment for unresectable hepatocellular carcinoma is surgical resection, liver transplant, ablation, and embolization.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12079
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
